Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[ d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors

Abstract

As a continuation of efforts to replace the metabolically labile methyl esters of lead alkenyldiarylmethanes (ADAMs) with stable bioisosteres, compounds bearing benzo[ d]isoxazole and oxazolidine-2-one rings were designed and evaluated as a new series of potent HIV-1 non-nucleoside reverse transcriptase inhibitors with anti-HIV activity. All of the resulting ADAMs were found to inhibit HIV-1 RT with poly(rC)·oligo(dG) as the template primer. The most promising compound in this series was ADAM 3, with EC 50 values of 40 nM (vs HIV-1 RF) and 20 nM (vs HIV-1 IIIB). Compound 3 also inhibited HIV-1 reverse transcriptase with an IC 50 of 0.91 μM. ADAM 4 has an antiviral EC 50 of 0.6 μM in CEM-SS cells and a plasma half-life of 51.4 min.